CN102532197A - 一类光亲和标记双功能探针分子及其制备方法和应用 - Google Patents
一类光亲和标记双功能探针分子及其制备方法和应用 Download PDFInfo
- Publication number
- CN102532197A CN102532197A CN2010106062959A CN201010606295A CN102532197A CN 102532197 A CN102532197 A CN 102532197A CN 2010106062959 A CN2010106062959 A CN 2010106062959A CN 201010606295 A CN201010606295 A CN 201010606295A CN 102532197 A CN102532197 A CN 102532197A
- Authority
- CN
- China
- Prior art keywords
- alkylidene group
- general formula
- double function
- probe molecules
- affinity labelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims abstract description 54
- 238000005222 photoaffinity labeling Methods 0.000 title abstract description 11
- 239000011521 glass Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 238000001228 spectrum Methods 0.000 claims abstract description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 48
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 46
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 238000002372 labelling Methods 0.000 claims description 22
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 17
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 16
- 238000011160 research Methods 0.000 claims description 14
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- -1 azido- Chemical class 0.000 claims description 9
- 229940043267 rhodamine b Drugs 0.000 claims description 9
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 9
- 239000012109 Alexa Fluor 568 Substances 0.000 claims description 8
- 229930003756 Vitamin B7 Natural products 0.000 claims description 8
- 239000011735 vitamin B7 Substances 0.000 claims description 8
- 235000011912 vitamin B7 Nutrition 0.000 claims description 8
- 125000004069 aziridinyl group Chemical group 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000700 radioactive tracer Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000008485 antagonism Effects 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 239000002904 solvent Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 239000000975 dye Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 229940125898 compound 5 Drugs 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003384 small molecules Chemical group 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- XLWJPQQFJNGUPA-UHFFFAOYSA-N 2,6-ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol Chemical compound OCC(C)(C)CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 XLWJPQQFJNGUPA-UHFFFAOYSA-N 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000006482 condensation reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000003906 phosphoinositides Chemical class 0.000 description 5
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000003513 alkali Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000006853 reporter group Chemical group 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001555 benzenes Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- WUUXOEFCIHOGRV-UHFFFAOYSA-N 3-(trifluoromethyl)-1h-diazirine Chemical compound FC(F)(F)C1=NN1 WUUXOEFCIHOGRV-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101100191373 Arabidopsis thaliana PRK6 gene Proteins 0.000 description 1
- 0 C*(C*NC(c1c(C(*)**)cccc1)=O)CP(C[C@](CN[C@](C)c1cc(C(O)=O)ccc1)O)(O)=O Chemical compound C*(C*NC(c1c(C(*)**)cccc1)=O)CP(C[C@](CN[C@](C)c1cc(C(O)=O)ccc1)O)(O)=O 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PTPUOMXKXCCSEN-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-dichloro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O PTPUOMXKXCCSEN-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- JGGVBBYJRQOPPA-BBRMVZONSA-N cyclohexylmethyl-[(2s)-3-[[(1s)-1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl]phosphinic acid Chemical compound C([C@@H](O)CN[C@@H](C)C=1C=C(Cl)C(Cl)=CC=1)P(O)(=O)CC1CCCCC1 JGGVBBYJRQOPPA-BBRMVZONSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106062959A CN102532197A (zh) | 2010-12-24 | 2010-12-24 | 一类光亲和标记双功能探针分子及其制备方法和应用 |
PCT/CN2011/084470 WO2012083872A1 (zh) | 2010-12-24 | 2011-12-22 | 一类光亲和标记双功能探针分子及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106062959A CN102532197A (zh) | 2010-12-24 | 2010-12-24 | 一类光亲和标记双功能探针分子及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102532197A true CN102532197A (zh) | 2012-07-04 |
Family
ID=46313184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106062959A Pending CN102532197A (zh) | 2010-12-24 | 2010-12-24 | 一类光亲和标记双功能探针分子及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102532197A (zh) |
WO (1) | WO2012083872A1 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710815A (zh) * | 2013-12-17 | 2015-06-17 | 中国科学院大连化学物理研究所 | 一种大斯托克斯位移和近红外荧光发射的新型罗丹荧类荧光染料及其合成方法 |
CN104710816B (zh) * | 2013-12-17 | 2017-05-10 | 中国科学院大连化学物理研究所 | 一种大斯托克斯位移和近红外荧光发射的新型罗丹明类荧光染料及其合成方法 |
WO2017161325A1 (en) * | 2016-03-17 | 2017-09-21 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
CN107703109A (zh) * | 2016-08-08 | 2018-02-16 | 华东理工大学 | 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用 |
CN108469427A (zh) * | 2018-02-07 | 2018-08-31 | 大连大学 | 一种表征等离子体诱导细胞内绝对钙离子浓度的方法 |
CN108503695A (zh) * | 2018-03-09 | 2018-09-07 | 南方医科大学南方医院 | 基于GnRH多肽衍生物的示踪剂及其制备方法和应用 |
WO2018170515A1 (en) * | 2017-03-17 | 2018-09-20 | The Broad Institute, Inc. | Methods for identifying and modulating co-occurant cellular phenotypes |
CN109369777A (zh) * | 2018-10-18 | 2019-02-22 | 大连理工大学 | 一类生物亲和探针分子及其制备方法与应用 |
CN109486235A (zh) * | 2018-11-10 | 2019-03-19 | 大连理工大学 | 一类具有细胞核靶向功能的dna染料化合物及应用 |
CN109503553A (zh) * | 2018-12-05 | 2019-03-22 | 西安交通大学 | 一种基于vegfr-2抑制剂b14的光亲合探针分子及其制备方法 |
CN110483398A (zh) * | 2019-08-30 | 2019-11-22 | 西安交通大学 | 一种含有生物可降解基团的光亲和链接体及制备方法和应用 |
WO2020024302A1 (zh) * | 2018-08-03 | 2020-02-06 | 苏州大学张家港工业技术研究院 | 一种紫外光触发交联型近红外分子探针及其制备方法与应用 |
CN111072681A (zh) * | 2019-12-11 | 2020-04-28 | 郑州大学 | 一种靶向细胞膜表面gaba受体荧光探针及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046675A1 (en) * | 1996-05-30 | 1997-12-11 | Novartis Ag | Metabotropic gaba[b] receptors, receptor-specific ligands and their uses |
CN1908661A (zh) * | 2005-08-04 | 2007-02-07 | 中国科学院上海药物研究所 | 一类小分子探针设计的结构模块、制备方法及用途 |
-
2010
- 2010-12-24 CN CN2010106062959A patent/CN102532197A/zh active Pending
-
2011
- 2011-12-22 WO PCT/CN2011/084470 patent/WO2012083872A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046675A1 (en) * | 1996-05-30 | 1997-12-11 | Novartis Ag | Metabotropic gaba[b] receptors, receptor-specific ligands and their uses |
CN1908661A (zh) * | 2005-08-04 | 2007-02-07 | 中国科学院上海药物研究所 | 一类小分子探针设计的结构模块、制备方法及用途 |
Non-Patent Citations (2)
Title |
---|
WOLFGANG FROESTL ET AL: "Ligands for expression cloning and isolation of GABAB receptors", 《IL FARMACO》 * |
XIN LI ET AL.: "Activity-Based Probe for Specific Photoaffinity Labeling γ-Aminobutyric Acid B (GABAB) Receptors on Living Cells: Design, Synthesis, and Biological Evaluation", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710815A (zh) * | 2013-12-17 | 2015-06-17 | 中国科学院大连化学物理研究所 | 一种大斯托克斯位移和近红外荧光发射的新型罗丹荧类荧光染料及其合成方法 |
CN104710816B (zh) * | 2013-12-17 | 2017-05-10 | 中国科学院大连化学物理研究所 | 一种大斯托克斯位移和近红外荧光发射的新型罗丹明类荧光染料及其合成方法 |
CN104710815B (zh) * | 2013-12-17 | 2017-05-10 | 中国科学院大连化学物理研究所 | 一种大斯托克斯位移和近红外荧光发射的新型罗丹荧类荧光染料及其合成方法 |
WO2017161325A1 (en) * | 2016-03-17 | 2017-09-21 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
US11427861B2 (en) | 2016-03-17 | 2022-08-30 | Massachusetts Institute Of Technology | Methods for identifying and modulating co-occurant cellular phenotypes |
CN107703109A (zh) * | 2016-08-08 | 2018-02-16 | 华东理工大学 | 二维硫化钼多肽复合材料及其在靶向cd47癌症标记中的应用 |
WO2018170515A1 (en) * | 2017-03-17 | 2018-09-20 | The Broad Institute, Inc. | Methods for identifying and modulating co-occurant cellular phenotypes |
CN108469427A (zh) * | 2018-02-07 | 2018-08-31 | 大连大学 | 一种表征等离子体诱导细胞内绝对钙离子浓度的方法 |
CN108503695A (zh) * | 2018-03-09 | 2018-09-07 | 南方医科大学南方医院 | 基于GnRH多肽衍生物的示踪剂及其制备方法和应用 |
CN108503695B (zh) * | 2018-03-09 | 2021-06-08 | 南方医科大学南方医院 | 基于GnRH多肽衍生物的示踪剂及其制备方法和应用 |
WO2020024302A1 (zh) * | 2018-08-03 | 2020-02-06 | 苏州大学张家港工业技术研究院 | 一种紫外光触发交联型近红外分子探针及其制备方法与应用 |
CN109369777A (zh) * | 2018-10-18 | 2019-02-22 | 大连理工大学 | 一类生物亲和探针分子及其制备方法与应用 |
CN109486235A (zh) * | 2018-11-10 | 2019-03-19 | 大连理工大学 | 一类具有细胞核靶向功能的dna染料化合物及应用 |
CN109503553A (zh) * | 2018-12-05 | 2019-03-22 | 西安交通大学 | 一种基于vegfr-2抑制剂b14的光亲合探针分子及其制备方法 |
CN109503553B (zh) * | 2018-12-05 | 2020-08-28 | 西安交通大学 | 一种基于vegfr-2抑制剂b14的光亲合探针分子及其制备方法 |
CN110483398A (zh) * | 2019-08-30 | 2019-11-22 | 西安交通大学 | 一种含有生物可降解基团的光亲和链接体及制备方法和应用 |
CN111072681A (zh) * | 2019-12-11 | 2020-04-28 | 郑州大学 | 一种靶向细胞膜表面gaba受体荧光探针及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2012083872A1 (zh) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102532197A (zh) | 一类光亲和标记双功能探针分子及其制备方法和应用 | |
Chen et al. | Identification of highly selective covalent inhibitors by phage display | |
Liu et al. | A multi-emissive fluorescent probe for the discrimination of glutathione and cysteine | |
CN107540608B (zh) | 4-取代萘酰亚胺类化合物及其应用 | |
AU2004206856C1 (en) | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | |
JP6876002B2 (ja) | 機能的要素を共有結合により係留させるための細胞透過性、細胞適合性、かつ開裂可能であるリンカー | |
US20090269793A1 (en) | Compounds and Kits for the Detection and the Quantification of Cell Apoptosis | |
JP2009510198A (ja) | 紫色レーザー励起性色素及びその使用方法 | |
Yang et al. | Discovery of 2-((4, 6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors | |
CA2501063A1 (en) | Substrates for o6-alkylguanine-dna alkyltransferase | |
US8435800B2 (en) | Activated labeling reagents and methods for preparing and using the same | |
CN102993205A (zh) | 一种高收率制备高纯度西地那非游离碱的纯化方法 | |
CN104910894B (zh) | 一种苯并咪唑类hERG钾离子通道的小分子荧光探针及其制备方法与应用 | |
Chen et al. | Discovery of novel benzimidazole derivatives as potent p300 bromodomain inhibitors with anti-proliferative activity in multiple cancer cells | |
WO2004078724A1 (ja) | リン酸化ペプチドの標識方法および選択的吸着方法、該方法に使用される錯体化合物、該錯体化合物の製造方法、および該錯体化合物の原料化合物 | |
CN110078663A (zh) | 一种母核为四氢喹啉的磺酰胺类化合物及其制备方法和应用 | |
CN106867512A (zh) | 一种检测抗生物素蛋白的比率型荧光探针及其合成方法和应用 | |
Xu et al. | An improved synthesis of a fluorophosphonate–polyethylene glycol–biotin probe and its use against competitive substrates | |
Jaime-Figueroa et al. | Discovery and synthesis of a novel and selective drug-like P2X1 antagonist | |
CN104034856A (zh) | 影响经典Wnt信号途径的药物的筛选方法及其应用 | |
CN110003160A (zh) | 一种蛇床子素腙类/酰腙类/磺酰腙类衍生物及其制备方法以及应用 | |
CN106701061B (zh) | 一种gpr120小分子荧光探针及其应用 | |
JP6670502B2 (ja) | 神経伝達物質受容体のリガンドスクリーニングシステムの開発 | |
Pete et al. | Synthesis of 5-substituted indole derivatives. Part 3: A facile synthesis of 5-chloromethyl-1H-indole-2-carboxylates: replacement of sulfonic acid functionality by chlorine | |
CN106928093B (zh) | 氰基非天然氨基酸的制备及其在生物正交拉曼检测上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HUAZHONG SCINECE AND TECHNOLOGY UNIV Effective date: 20131225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131225 Address after: 200031 No. 294, Taiyuan Road, Shanghai, Xuhui District Applicant after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Applicant after: Huazhong University of Science and Technology Address before: 200031 No. 294, Taiyuan Road, Shanghai, Xuhui District Applicant before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Pudong Zhangjiang Zuchongzhi road 201203 Shanghai City No. 555 Applicant after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Applicant after: Huazhong University of Science and Technology Address before: 200031 No. 294, Taiyuan Road, Shanghai, Xuhui District Applicant before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Applicant before: Huazhong University of Science and Technology |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120704 |